Stifel raises target for Incyte stock from USD 145.00 to USD 157.00

Published on 10/05/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 37.70 percent to USD 1.67 billion. Incyte stock costs EUR 103.15 on October 5, 2026 versus EUR 102.45, plus 0.68 percent.

Extreme Makrofotografie einer Pharmakapsel mit blauem und weißem Granulat — Incyte Wirkstoffkapsel in extremer Makroaufnahme zeigt Granulat, steht für Innovation ISIN US45337C1027, Illustration mit AI erstellt.

Incyte (ISIN US45337C1027) was trading at EUR 103.15 at Lang & Schwarz on October 5, 2026 at 3:11 p.m. CEST, up 0.68 percent versus the prior close of EUR 102.45. On October 5, 2026, Stifel Nicolaus raised its Incyte price target from USD 145.00 to USD 157.00 and reaffirmed a Buy rating, according to MarketBeat.

Stifel targets pipeline growth

The new USD 157.00 target is USD 12.00 above Stifel's previous USD 145.00 target. The analyst action gives investors a concrete valuation marker in dollars, while the German quote remains a separate euro reference.

Stifel's view centers on Incyte's late-stage pipeline and expected data catalysts, according to Investing.com. The report said the pipeline could achieve more than USD 10 billion in peak worldwide sales, although that figure is a forecast rather than reported revenue.

Second-quarter revenue jumps

Incyte's second-quarter 2026 revenue reached USD 1.67 billion, compared with USD 1.50 billion expected by analysts, according to MarketBeat. Revenue increased 37.70 percent from the same quarter of the prior year, while earnings per share reached USD 3.09 versus a USD 2.15 consensus estimate.

The comparison matters because it combines a current operating result with the valuation case behind the target increase. Incyte's latest quarterly net income was USD 585.61 million, compared with USD 405.00 million in the year-earlier quarter, according to Markets Insider.

Euro quote and U.S. range

Incyte's Lang & Schwarz quote of EUR 103.15 stood below the prior close of EUR 102.45 by EUR 0.70, a daily gain of 0.68 percent. On the primary NASDAQ listing, the stock's 52-week range was USD 82.82 to USD 132.60 and market capitalization was USD 23.4 billion as of October 5, 2026.

The further course of trading is shown by the continuously updated real-time quote of Incyte stock.